← Evidence map

ArticleCancers2026

Durvalumab Plus High-Dose Radiation in NSCLC III: Long-Term Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Katharina Hörmandinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Durvalumab Plus High-Dose Radiation in NSCLC III: Long-Term Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). | OpenQuestion